Over the past year, Brexit and the COVID-19 pandemic have represented two major threats to the smooth functioning of the UK generics and biosimilars market. And after discussing how far the country’s off-patent industry has come over the past 25 years (Also see "BGMA’s Smith Reflects On 25 Years Of Progress" - Generics Bulletin, 1 April, 2021.), departing British Generic Manufacturers Association leader Warwick Smith turned his attention to these two more recent challenges in the second part of our exclusive interview.
Casting his mind back a year to the early days of the pandemic, Smith described how the UK generics industry...
